Javascript must be enabled to continue!
Formulation and Characterization of Fe3O4@PEG Nanoparticles Loaded Sorafenib; Molecular Studies and Evaluation of Cytotoxicity in Liver Cancer Cell Lines
View through CrossRef
Iron oxide nanoparticles are one of the nanocarriers that are suitable for novel drug delivery systems due to low toxicity, biocompatibility, loading capacity, and controlled drug delivery to cancer cells. The purpose of the present study is the synthesis of coated iron oxide nanoparticles for the delivery of sorafenib (SFB) and its effects on cancer cells. In this study, Fe3O4 nanoparticles were synthesized by the co-precipitation method, and then sorafenib was loaded onto PEG@Fe3O4 nanoparticles. FTIR was used to ensure polyethylene glycol (PEG) binding to nanoparticles and loading the drug onto the nanoshells. A comparison of the mean size and the crystalline structure of nanoparticles was performed by TEM, DLS, and X-ray diffraction patterns. Then, cell viability was obtained by the MTT assay for 3T3 and HepG2 cell lines. According to FT-IR results, the presence of O–H and C–H bands at 3427 cm–1 and 1420 cm–1 peak correlate with PEG binding to nanoparticles. XRD pattern showed the cubic spinel structure of trapped magnetite nanoparticles carrying medium. The magnetic properties of nanoparticles were examined by a vibrating-sample magnetometer (VSM). IC50 values at 72 h for treatment with carriers of Fe3O4@PEG nanoparticle for the HepG2 cell line was 15.78 μg/mL (p < 0.05). This study showed that Fe3O4 nanoparticles coated by polyethylene glycol and using them in the drug delivery process could be beneficial for increasing the effect of sorafenib on cancer cells.
Title: Formulation and Characterization of Fe3O4@PEG Nanoparticles Loaded Sorafenib; Molecular Studies and Evaluation of Cytotoxicity in Liver Cancer Cell Lines
Description:
Iron oxide nanoparticles are one of the nanocarriers that are suitable for novel drug delivery systems due to low toxicity, biocompatibility, loading capacity, and controlled drug delivery to cancer cells.
The purpose of the present study is the synthesis of coated iron oxide nanoparticles for the delivery of sorafenib (SFB) and its effects on cancer cells.
In this study, Fe3O4 nanoparticles were synthesized by the co-precipitation method, and then sorafenib was loaded onto PEG@Fe3O4 nanoparticles.
FTIR was used to ensure polyethylene glycol (PEG) binding to nanoparticles and loading the drug onto the nanoshells.
A comparison of the mean size and the crystalline structure of nanoparticles was performed by TEM, DLS, and X-ray diffraction patterns.
Then, cell viability was obtained by the MTT assay for 3T3 and HepG2 cell lines.
According to FT-IR results, the presence of O–H and C–H bands at 3427 cm–1 and 1420 cm–1 peak correlate with PEG binding to nanoparticles.
XRD pattern showed the cubic spinel structure of trapped magnetite nanoparticles carrying medium.
The magnetic properties of nanoparticles were examined by a vibrating-sample magnetometer (VSM).
IC50 values at 72 h for treatment with carriers of Fe3O4@PEG nanoparticle for the HepG2 cell line was 15.
78 μg/mL (p < 0.
05).
This study showed that Fe3O4 nanoparticles coated by polyethylene glycol and using them in the drug delivery process could be beneficial for increasing the effect of sorafenib on cancer cells.
Related Results
Research of Synergetic Reversal in Adriamycin - Resistance by the Application of Magnetic Nanoparticle of Fe3O4 and Tetrandrine in K562/A02 Leukemic Cells.
Research of Synergetic Reversal in Adriamycin - Resistance by the Application of Magnetic Nanoparticle of Fe3O4 and Tetrandrine in K562/A02 Leukemic Cells.
Objective: To prepare functionalized Fe3O4-magnetic nanoparticles(Fe3O4-MNPs) loaded with adriamycin(ADM) or Fe3O4-MNPs co-polymerized with ADM and tetrandrine(Tet) to investigate ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia.
Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia.
Abstract
Abstract 2060
Poster Board II-37
Introduction:
The Flt3-internal tandem duplication can b...
Targeted delivery of doxorubicin
Targeted delivery of doxorubicin
<p>Cancer is a group of diseases caused by uncontrolled cellular proliferation and dissemination. After heart disease, cancer is the second most common cause of death in the ...
Antimicrobial activity of ciprofloxacin-coated gold nanoparticles on selected pathogens
Antimicrobial activity of ciprofloxacin-coated gold nanoparticles on selected pathogens
Antibiotic resistance amongst bacterial pathogens is a crisis that has been worsening over recent decades, resulting in serious and often fatal infections that cannot be treated by...
Multifunctional Silver Nanoparticles: Synthesis and Applications
Multifunctional Silver Nanoparticles: Synthesis and Applications
Multifunctional silver nanoparticles have attracted widely due to their potential applications. Based on the properties of individual silver nanoparticles, such as plasmonic and an...
Abstract 266: Differential collective cell migratory behaviors modulated by phospholipid nanoparticles
Abstract 266: Differential collective cell migratory behaviors modulated by phospholipid nanoparticles
Abstract
Phospholipid nanoparticles have been actively explored for biological and biomedical applications. These nanoparticles display excellent cargo encapsulation...
YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin
YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin
Abstract
Background
Sorafenib is the standard first-line treatment for advanced hepatocellular carcinoma (HCC), but its use is hampered by the secondary drug resistance. Y...

